|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C1orf50 |
Gene summary for C1ORF50 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C1orf50 | Gene ID | 79078 |
| Gene name | chromosome 1 open reading frame 50 | |
| Gene Alias | C1orf50 | |
| Cytomap | 1p34.2 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9BV19 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79078 | C1orf50 | LZE4T | Human | Esophagus | ESCC | 6.35e-03 | 1.21e-01 | 0.0811 |
| 79078 | C1orf50 | LZE7T | Human | Esophagus | ESCC | 1.40e-08 | 3.34e-01 | 0.0667 |
| 79078 | C1orf50 | LZE8T | Human | Esophagus | ESCC | 1.10e-02 | 1.33e-01 | 0.067 |
| 79078 | C1orf50 | LZE20T | Human | Esophagus | ESCC | 1.20e-05 | 2.08e-01 | 0.0662 |
| 79078 | C1orf50 | LZE22T | Human | Esophagus | ESCC | 1.57e-03 | 2.22e-01 | 0.068 |
| 79078 | C1orf50 | LZE24T | Human | Esophagus | ESCC | 1.89e-10 | 2.52e-01 | 0.0596 |
| 79078 | C1orf50 | LZE6T | Human | Esophagus | ESCC | 1.62e-02 | 1.56e-01 | 0.0845 |
| 79078 | C1orf50 | P1T-E | Human | Esophagus | ESCC | 5.20e-08 | 2.95e-01 | 0.0875 |
| 79078 | C1orf50 | P2T-E | Human | Esophagus | ESCC | 4.24e-18 | 3.03e-01 | 0.1177 |
| 79078 | C1orf50 | P4T-E | Human | Esophagus | ESCC | 1.17e-15 | 3.28e-01 | 0.1323 |
| 79078 | C1orf50 | P5T-E | Human | Esophagus | ESCC | 1.35e-23 | 3.98e-01 | 0.1327 |
| 79078 | C1orf50 | P8T-E | Human | Esophagus | ESCC | 3.89e-12 | 1.98e-01 | 0.0889 |
| 79078 | C1orf50 | P9T-E | Human | Esophagus | ESCC | 2.41e-06 | 1.76e-01 | 0.1131 |
| 79078 | C1orf50 | P10T-E | Human | Esophagus | ESCC | 9.86e-34 | 5.25e-01 | 0.116 |
| 79078 | C1orf50 | P11T-E | Human | Esophagus | ESCC | 1.06e-12 | 3.76e-01 | 0.1426 |
| 79078 | C1orf50 | P12T-E | Human | Esophagus | ESCC | 3.52e-19 | 3.31e-01 | 0.1122 |
| 79078 | C1orf50 | P15T-E | Human | Esophagus | ESCC | 6.21e-15 | 2.84e-01 | 0.1149 |
| 79078 | C1orf50 | P16T-E | Human | Esophagus | ESCC | 2.03e-09 | 1.70e-01 | 0.1153 |
| 79078 | C1orf50 | P17T-E | Human | Esophagus | ESCC | 5.25e-15 | 4.69e-01 | 0.1278 |
| 79078 | C1orf50 | P19T-E | Human | Esophagus | ESCC | 3.75e-07 | 3.76e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C1orf50 | SNV | Missense_Mutation | novel | c.14N>T | p.Ala5Val | p.A5V | Q9BV19 | protein_coding | tolerated_low_confidence(0.25) | benign(0) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| C1orf50 | SNV | Missense_Mutation | rs762133303 | c.563C>T | p.Pro188Leu | p.P188L | Q9BV19 | protein_coding | tolerated_low_confidence(0.08) | benign(0.003) | TCGA-A6-6648-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | PD |
| C1orf50 | SNV | Missense_Mutation | c.299N>G | p.His100Arg | p.H100R | Q9BV19 | protein_coding | tolerated(0.51) | benign(0) | TCGA-AA-3975-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| C1orf50 | SNV | Missense_Mutation | c.512N>A | p.Ala171Asp | p.A171D | Q9BV19 | protein_coding | tolerated(0.29) | benign(0.104) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1orf50 | SNV | Missense_Mutation | novel | c.508N>T | p.Asp170Tyr | p.D170Y | Q9BV19 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C1orf50 | SNV | Missense_Mutation | c.418T>C | p.Trp140Arg | p.W140R | Q9BV19 | protein_coding | deleterious(0.02) | possibly_damaging(0.542) | TCGA-B5-A11U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| C1orf50 | SNV | Missense_Mutation | c.356N>G | p.Ile119Ser | p.I119S | Q9BV19 | protein_coding | deleterious(0) | possibly_damaging(0.783) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C1orf50 | SNV | Missense_Mutation | novel | c.407C>A | p.Ser136Tyr | p.S136Y | Q9BV19 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-DF-A2KV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C1orf50 | SNV | Missense_Mutation | rs750596118 | c.485N>T | p.Pro162Leu | p.P162L | Q9BV19 | protein_coding | deleterious(0.02) | possibly_damaging(0.784) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C1orf50 | SNV | Missense_Mutation | novel | c.546G>T | p.Gln182His | p.Q182H | Q9BV19 | protein_coding | tolerated(0.09) | possibly_damaging(0.891) | TCGA-44-5644-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |